Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Investing Cash Flow history
Currency unavailable · from the cash flow
No Investing Cash Flow data reported for this period type.
Investing Cash Flow vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $293.7M USD | +578.5% | +656.7% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $170.56M USD | +59.1% | +228.6% | 852.8% |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $124.43M USD | +0.7% | — | — |
| LTM Mar 2026 | $71.19M USD | +59.3% | +23.9% | 32.7% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $57.94M USD | -8.8% | — | — |
| LTM Mar 2026 | $43.35M USD | -36.4% | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $42.41M USD | — | — | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +29.9% | +228.6% | 442.8% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.